Searching On:

Disease:

Gene:

ERBB2 (HER2), Overexpression

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse ERBB2 (HER2)  - General Description Erbb2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ErbB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the HER2 gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. The presence of amplified HER2 has been reported in breast tumors, esophageal tumors, gastric cancers, ovarian tumors and bladder cancer. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2)protein have also been found in certain tumors. Testing for genetic alterations in ERBB2 (HER2) can be performed at the MGH, or other large academic centers. Treatment and Clinical Trials testing new therapies are also available at MGH Cancer Center. Source: Genetics Home ReferenceErbb2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ErbB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the HER2 gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. The presence of amplified HER2 has been reported in breast tumors, esophageal tumors, gastric cancers, ovarian tumors and bladder cancer. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2)protein have also been found in certain tumors. Testing for genetic alterations in ERBB2 (HER2) can be performed at the MGH, or other large academic centers. Treatment and Clinical Trials testing new therapies are also available at MGH Cancer Center. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
Erbb2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ErbB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the HER2 gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. The presence of amplified HER2 has been reported in breast tumors, esophageal tumors, gastric cancers, ovarian tumors and bladder cancer. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2)protein have also been found in certain tumors.

Testing for genetic alterations in ERBB2 (HER2) can be performed at the MGH, or other large academic centers. Treatment and Clinical Trials testing new therapies are also available at MGH Cancer Center.

Source: Genetics Home Reference
Erbb2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ErbB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the HER2 gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. The presence of amplified HER2 has been reported in breast tumors, esophageal tumors, gastric cancers, ovarian tumors and bladder cancer. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2)protein have also been found in certain tumors.

Testing for genetic alterations in ERBB2 (HER2) can be performed at the MGH, or other large academic centers. Treatment and Clinical Trials testing new therapies are also available at MGH Cancer Center.

Source: Genetics Home Reference
PubMed ID's
15864276, 9130710, 15457249, 16397024, 18772890, 16843263, 16988931, 22899400
Expand Collapse Overexpression  in ERBB2 (HER2)
In some tumors, ERBB2 (Her2/EGFR) has been found to be expressed at a much higher level than in normal cells. This is called overexpression. The overexpression of a gene results in a much higher level of the ERBB2 (HER2/EGFR) protein in cancer cells, which drives tumor cell growth. Testing for overexpression of ERBB2/HER2/EGFR (all names for the same gene) is performed at MGH. Treatment and clinical trials for ERBB2 overexpression are underway at MGH and other large academic centers.
In some tumors, ERBB2 (Her2/EGFR) has been found to be expressed at a much higher level than in normal cells. This is called overexpression. The overexpression of a gene results in a much higher level of the ERBB2 (HER2/EGFR) protein in cancer cells, which drives tumor cell growth. Testing for overexpression of ERBB2/HER2/EGFR (all names for the same gene) is performed at MGH. Treatment and clinical trials for ERBB2 overexpression are underway at MGH and other large academic centers.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing Results: 1-10 of 11 Per Page:
12Next »
Protocol # Title Location Status Match
NCT02657343 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. MGH Open GM
NCT02689284 Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer MGH Open GM
NCT02491099 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma MGH Open G
NCT02715531 A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors MGH Open G
NCT02716116 A Trial of AP32788 in Non-Small Cell Lung Cancer A Trial of AP32788 in Non-Small Cell Lung Cancer MGH Open G
NCT01953926 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification MGH Open G
NCT02580448 CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) MGH Open G
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors MGH Open G
NCT02952729 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 MGH Open G
NCT02326974 T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA MGH Open G
Trial Status: Showing Results: 1-10 of 11 Per Page:
12Next »

Share with your Physican

Print information for your Physician.

Print information